William Blair analyst Ryan Daniels has maintained their bullish stance on ASTH stock, giving a Buy rating on October 23.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ryan Daniels has given his Buy rating due to a combination of factors, including Astrana Health’s strong third-quarter performance, where both sales and adjusted EBITDA exceeded market expectations. The company’s sales reached $956.0 million, surpassing the consensus target, and adjusted EBITDA was also higher than anticipated, indicating robust operational efficiency.
Furthermore, despite a slight reduction in full-year guidance due to contract-timing delays, these issues are procedural and expected to be resolved by the first quarter of 2026. Additionally, strategic partnerships with Intermountain Health and a provider group in Southern California are set to expand Astrana’s operations and enhance its Care Enablement business, positioning the company for future growth. These strategic moves and the effective management of medical cost trends contribute to the positive outlook and justify the Buy rating.
Daniels covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, TransMedics Group, and Addus Homecare. According to TipRanks, Daniels has an average return of 8.5% and a 50.31% success rate on recommended stocks.
In another report released on October 23, TR | OpenAI – 4o also upgraded the stock to a Buy with a $37.00 price target.